Regulatory mechanisms of the plasma contact system

Thrombosis Research

Volumn 129, Issue SUPPL. 2, 2012, Pages

  Maas, Coen ^a,b   Renné, Thomas ^b  

^a UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^b KAROLINSKA INSTITUTE   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

BLOOD CLOTTING FACTOR; BLOOD CLOTTING FACTOR 12; COMPLEMENT COMPONENT C1S INHIBITOR; ENZYME PRECURSOR; FIBRONECTIN; PLASMA KALLIKREIN;

BLOOD CLOTTING; BLOOD COMPONENT; CRYSTAL STRUCTURE; HEMOSTASIS; NONHUMAN; PRIORITY JOURNAL; REGULATORY MECHANISM; REVIEW; THROMBOSIS;

EID: 84859796179     PISSN: 00493848     EISSN: 18792472     Source Type: Journal    
DOI: 10.1016/j.thromres.2012.02.039     Document Type: Article

References (59)

1. Renne T, Dedio J, David G, Muller-Esterl W. High molecular weight kininogen utilizes heparan sulfate proteoglycans for accumulation on endothelial cells. J Biol Chem 2000;275:33688-96.
2. Renne T, Dedio J, Meijers JC, Chung D, Muller-Esterl W. Mapping of the discontinuous H-kininogen binding site of plasma prekallikrein. Evidence for a critical role of apple domain-2. J Biol Chem 1999;274:25777-84.
3. Renne T, Schuh K, Muller-Esterl W. Local bradykinin formation is controlled by glycosaminoglycans. J Immunol 2005;175:3377-85. (Pubitemid 41170560)
4. Renne T. The procoagulant and proinflammatory plasma contact system. Semin Immunopathol 2012;34:31-41.
5. Maas C, Oschatz C, Renne T. The plasma contact system 2.0. Semin Thromb Hemost 2011;37:375-81.
6. Pixley RA, Stumpo LG, Birkmeyer K, Silver L, Colman RW. A monoclonal antibody recognizing an icosapeptide sequence in the heavy chain of human factor XII inhibits surface-catalyzed activation. J Biol Chem 1987;262:10140-5. (Pubitemid 17103064)
7. Citarella F, te Velthuis H, Helmer-Citterich M, Hack CE. Identification of a putative binding site for negatively charged surfaces in the fibronectin type II domain of human factor XII-an immunochemical and homology modeling approach. Thromb Haemost 2000;84:1057-65. (Pubitemid 32014043)
8. Citarella F, Ravon DM, Pascucci B, Felici A, Fantoni A, Hack CE. Structure/function analysis of human factor XII using recombinant deletion mutants. Evidence for an additional region involved in the binding to negatively charged surfaces. Eur J Biochem 1996;238:240-9.
9. Clarke BJ, Cote HC, Cool DE, Clark-Lewis I, Saito H, Pixley RA, et al. Mapping of a putative surface-binding site of human coagulation factor XII. J Biol Chem 1989;264:11497-502. (Pubitemid 19168890)
10. Samuel M, Pixley RA, Villanueva MA, Colman RW, Villanueva GB. Human factor XII (Hageman factor) autoactivation by dextran sulfate. Circular dichroism, fluorescence, and ultraviolet difference spectroscopic studies. J Biol Chem 1992;267: 19691-7.
11. Miller G, Silverberg M, Kaplan AP. Autoactivatability of human Hageman factor (factor XII). Biochem Biophys Res Commun 1980;92:803-10. (Pubitemid 10119552)
12. Asmis LM, Sulzer I, Furlan M, Lammle B. Prekallikrein deficiency: the characteristic normalization of the severely prolonged aPTT following increased preincubation time is due to autoactivation of factor XII. Thromb Res 2002;105: 463-70. (Pubitemid 34686904)
13. Hovinga JK, Schaller J, Stricker H, Wuillemin WA, Furlan M, Lammle B. Coagulation factor XII Locarno: the functional defect is caused by the amino acid substitution Arg 353→Pro leading to loss of a kallikrein cleavage site. Blood 1994;84: 1173-81. (Pubitemid 24245882)
14. Citarella F, Wuillemin WA, Lubbers YT, Hack CE. Initiation of contact system activation in plasma is dependent on factor XII autoactivation and not on enhanced susceptibility of factor XII for kallikrein cleavage. Br J Haematol 1997;99:197-205. (Pubitemid 27461349)
15. Ravon DM, Citarella F, Lubbers YT, Pascucci B, Hack CE. Monoclonal antibody F1 binds to the kringle domain of factor XII and induces enhanced susceptibility for cleavage by kallikrein. Blood 1995;86:4134-43.
16. Revak SD, Cochrane CG. The relationship of structure and function in human Hageman factor. The association of enzymatic and binding activities with separate regions of the molecule. J Clin Invest 1976;57:852-60.
17. Herwald H, Renne T, Meijers JC, Chung DW, Page JD, Colman RW, et al. Mapping of the discontinuous kininogen binding site of prekallikrein. A distal binding segment is located in the heavy chain domain A4. J Biol Chem 1996;271:13061-7.
18. Revak SD, Cochrane CG, Bouma BN, Griffin JH. Surface and fluid phase activities of two forms of activated Hageman factor produced during contact activation of plasma. J Exp Med 1978;147:719-29. (Pubitemid 8303486)
19. Baglia F, Jameson B, Walsh P. Identification and characterization for a binding site for factor XIIa in the apple 4 domain of coagulation factor XI. J Biol Chem 1993;268:3838-44. (Pubitemid 23072911)
20. Herwald H, Renne T, Meijers JC, Chung DW, Page JD, Colman RW, et al. Mapping of the discontinuous kininogen binding site of prekallikrein. A distal binding segment is located in the heavy chain domain A4. J Biol Chem 1996;271:13061-7.
21. Renne T, Dedio J, Meijers JC, Chung D, Muller-Esterl W. Mapping of the discontinuous H-kininogen binding site of plasma prekallikrein. Evidence for a critical role of apple domain-2. J Biol Chem 1999;274:25777-84.
22. Seligsohn U, Osterud B, Brown SF, Griffin JH, Rapaport SI. Activation of human factor VII in plasma and in purified systems: roles of activated factor IX, kallikrein, and activated factor XII. J Clin Invest 1979;64:1056-65. (Pubitemid 10232584)
23. Ghebrehiwet B, Randazzo BP, Dunn JT, Silverberg M, Kaplan AP. Mechanisms of activation of the classical pathway of complement by Hageman factor fragment. J Clin Invest 1983;71:1450-6. (Pubitemid 13098935)
24. Kluft C, Dooijewaard G, Emeis JJ. Role of the contact system in fibrinolysis. Semin Thromb Hemost 1987;13:50-68. (Pubitemid 17034603)
25. Levi M, Hack CE, de Boer JP, Brandjes DP, Buller HR, ten Cate JW. Reduction of contact activation related fibrinolytic activity in factor XII deficient patients. Further evidence for the role of the contact system in fibrinolysis in vivo. J Clin Invest 1991;88:1155-60.
26. Muller F, Renne T. Novel roles for factor XII-driven plasma contact activation system. Curr Opin Hematol 2008;15:516-21.
27. Colman RW, Wachtfogel YT, Kucich U, Weinbaum G, Hahn S, Pixley RA, et al. Effect of cleavage of the heavy chain of human plasma kallikrein on its functional properties. Blood 1985;65:311-8. (Pubitemid 15163566)
28. Schapira M, Silver LD, Scott CF, Schmaier AH, Prograis Jr LJ, Curd JG, et al. Prekallikrein activation and high-molecular-weight kininogen consumption in hereditary angioedema. N Engl J Med 1983;308:1050-3. (Pubitemid 13124892)
29. Cichon S, Martin L, Hennies HC, Muller F, Van Driessche K, Karpushova A, et al. Increased activity of coagulation factor XII (Hageman factor) causes hereditary angioedema type III. Am J Hum Genet 2006;79:1098-104. (Pubitemid 44853481)
30. Kannemeier C, Shibamiya A, Nakazawa F, Trusheim H, Ruppert C, Markart P, et al. Extracellular RNA constitutes a natural procoagulant cofactor in blood coagulation. Proc Natl Acad Sci U S A 2007;104:6388-93. (Pubitemid 47186104)
31. Wilner GD, Nossel HL, LeRoy EC. Activation of Hageman factor by collagen. J Clin Invest 1968;47:2608-15.
32. van der Meijden PE, Munnix IC, Auger JM, Govers-Riemslag JW, Cosemans JM, Kuijpers MJ, et al. Dual role of collagen in factor XII-dependent thrombus formation. Blood 2009;114:881-90.
33. Smith SA, Mutch NJ, Baskar D, Rohloff P, Docampo R, Morrissey JH. Polyphosphate modulates blood coagulation and fibrinolysis. Proc Natl Acad Sci U S A 2006;103: 903-8 Epub 2006 Jan 12.
34. Muller F, Mutch NJ, Schenk WA, Smith SA, Esterl L, Spronk HM, et al. Platelet polyphosphates are proinflammatory and procoagulant mediators in vivo. Cell 2009;139:1143-56.
35. Renne T, Pozgajova M, Gruner S, Schuh K, Pauer HU, Burfeind P, et al. Defective thrombus formation in mice lacking coagulation factor XII. J Exp Med 2005;202: 271-81. (Pubitemid 41043823)
36. Morrison DC, Cochrane CG. Direct evidence for Hageman factor (factor XII) activation by bacterial lipopolysaccharides (endotoxins). J Exp Med 1974;140:797-811.
37. Pixley R, DeLa Cadena R, Page J, Kauffman N, Wyshock E, Chang A, et al. The contact system contributes to hypotension but not disseminated intravascular coagulation in lethal bacteremia: In vivo use of a monoclonal anti-factor XII antibody to block contact activation in baboons. J Clin Invest 1993;91:61.
38. Iwaki T, Cruz-Topete D, Castellino FJ. A complete factor XII deficiency does not affect coagulopathy, inflammatory responses, and lethality, but attenuates early hypotension in endotoxemic mice. J Thromb Haemost 2008;6:1993-5.
39. Shibayama Y, Joseph K, Nakazawa Y, Ghebreihiwet B, Peerschke EI, Kaplan AP. Zinc-dependent activation of the plasma kinin-forming cascade by aggregated beta amyloid protein. Clin Immunol 1999;90:89-99. (Pubitemid 29162187)
40. Bergamaschini L, Parnetti L, Pareyson D, Canziani S, Cugno M, Agostoni A. Activation of the contact system in cerebrospinal fluid of patients with Alzheimer disease [In Process Citation]. Alzheimer Dis Assoc Disord 1998;12:102-8. (Pubitemid 29108217)
41. Maas C, Govers-Riemslag JW, Bouma B, Schiks B, Hazenberg BP, Lokhorst HM, et al. Misfolded proteins activate factor XII in humans, leading to kallikrein formation without initiating coagulation. J Clin Invest 2008;118:3208-18.
42. Kishimoto TK, Viswanathan K, Ganguly T, Elankumaran S, Smith S, Pelzer K, et al. Contaminated heparin associated with adverse clinical events and activation of the contact system. N Engl J Med 2008;358:2457-67. (Pubitemid 351793019)
43. Oschatz C, Maas C, Lecher B, Jansen T, Bjorkqvist J, Tradler T, et al. Mast cells increase vascular permeability by heparin-initiated bradykinin formation in vivo. Immunity 2011;34:258-68.
44. Tazi S, Tans G, Hemker HC, Nigretto JM. Autoactivation of human blood coagulation factor XII on dextran derivatives of different molecular weight. Thromb Res 1992;67:665-76.
45. Kleinschnitz C, Stoll G, Bendszus M, Schuh K, Pauer HU, Burfeind P, et al. Targeting coagulation factor XII provides protection from pathological thrombosis in cerebral ischemia without interfering with hemostasis. J Exp Med 2006;203:513-8.
46. Hagedorn I, Schmidbauer S, Pleines I, Kleinschnitz C, Kronthaler U, Stoll G, et al. Factor XIIa inhibitor recombinant human albumin Infestin-4 abolishes occlusive arterial thrombus formation without affecting bleeding. Circulation 2010;121: 1510-7.
47. Revenko AS, Gao D, Crosby JR, Bhattacharjee G, Zhao C, May C, et al. Selective depletion of plasma prekallikrein or coagulation factor XII inhibits thrombosis in mice without increased risk of bleeding. Blood 2011;118:5302-11.
48. Zhang H, Lowenberg EC, Crosby JR, Macleod AR, Zhao C, Gao D, et al. Inhibition of the intrinsic coagulation pathway factor XI by antisense oligonucleotides: a novel antithrombotic strategy with lowered bleeding risk. Blood 2010;116:4684-92.
49. Doggen CJ, Rosendaal FR, Meijers JC. Levels of intrinsic coagulation factors and the risk of myocardial infarction among men: Opposite and synergistic effects of factors XI and XII. Blood 2006;108:4045-51. (Pubitemid 44913273)
50. Endler G, Marsik C, Jilma B, Schickbauer T, Quehenberger P, Mannhalter C. Evidence of a U-shaped association between factor XII activity and overall survival. J Thromb Haemost 2007;5:1143-8. (Pubitemid 46902114)
51. Govers-Riemslag JW, Smid M, Cooper JA, Bauer KA, Rosenberg RD, Hack CE, et al. The plasma kallikrein-kinin system and risk of cardiovascular disease in men. J Thromb Haemost 2007;5:1896-903. (Pubitemid 47288948)
52. Siegerink B, Govers-Riemslag JW, Rosendaal FR, Ten Cate H, Algra A. Intrinsic coagulation activation and the risk of arterial thrombosis in young women: results from the Risk of Arterial Thrombosis in relation to Oral contraceptives (RATIO) case-control study. Circulation 2010;122:1854-61.
53. Girolami A, Allemand E, Bertozzi I, Candeo N, Marun S, Girolami B. Thrombotic events in patients with congenital prekallikrein deficiency: a critical evaluation of all reported cases. Acta Haematol 2010;123:210-4.
54. Harris MG, Exner T, Rickard KA, Kronenberg H. Multiple cerebral thrombosis in Fletcher factor (prekallikrein) deficiency: a case report. Am J Hematol 1985;19: 387-93. (Pubitemid 15004921)
55. Cheng Q, Tucker EI, Pine MS, Sisler I, Matafonov A, Sun MF, et al. A role for factor XIIa-mediated factor XI activation in thrombus formation in vivo. Blood 2010;116:3981-9.
56. Mao G, Jin Kunapuli. Coagulation factor XIIa activates platelets and is the physiologic agonist of protease activated receptor 3. Blood 2009;114:770A.
57. MacQuarrie JL, Stafford AR, Yau JW, Leslie BA, Vu TT, Fredenburgh JC, et al. Histidine-rich glycoprotein binds factor XIIa with high affinity and inhibits contact-initiated coagulation. Blood 2011;117:4134-41.
58. Konings J, Govers-Riemslag JW, Philippou H, Mutch NJ, Borissoff JI, Allan P, et al. Factor XIIa regulates the structure of the fibrin clot independently of thrombin generation through direct interaction with fibrin. Blood 2011;118:3942-51.
59. Fatah K, Silveira A, Tornvall P, Karpe F, Blomback M, Hamsten A. Proneness to formation of tight and rigid fibrin gel structures in men with myocardial infarction at a young age. Thromb Haemost 1996;76:535-40. (Pubitemid 26372007)